[go: up one dir, main page]

HK1048999A1 - 氮雜䓬吲衍生物，它們的製備和應用 - Google Patents

氮雜䓬吲衍生物，它們的製備和應用 Download PDF

Info

Publication number
HK1048999A1
HK1048999A1 HK03101179.8A HK03101179A HK1048999A1 HK 1048999 A1 HK1048999 A1 HK 1048999A1 HK 03101179 A HK03101179 A HK 03101179A HK 1048999 A1 HK1048999 A1 HK 1048999A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
substituted
phenyl
compound
hydrogen
Prior art date
Application number
HK03101179.8A
Other languages
English (en)
Chinese (zh)
Inventor
W‧卢比施
W‧盧比施
M‧考克
T‧霍格
R‧格兰德尔
R‧穆勒
S‧舒尔特
R‧格蘭德爾
S‧舒爾特
Original Assignee
巴斯福股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/de
Priority claimed from DE10039610A external-priority patent/DE10039610A1/de
Application filed by 巴斯福股份公司 filed Critical 巴斯福股份公司
Publication of HK1048999A1 publication Critical patent/HK1048999A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK03101179.8A 1999-09-28 2000-09-15 氮雜䓬吲衍生物，它們的製備和應用 HK1048999A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (de) 1999-09-28 1999-09-28 Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE19946289.5 1999-09-28
DE10039610A DE10039610A1 (de) 2000-08-09 2000-08-09 Azepinoindol-Derivate, deren Herstellung und Anwendung
DE10039610.0 2000-08-09
PCT/EP2000/009024 WO2001023390A2 (de) 1999-09-28 2000-09-15 Azepinoindol-derivate, deren herstellung und anwendung

Publications (1)

Publication Number Publication Date
HK1048999A1 true HK1048999A1 (zh) 2003-04-25

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101179.8A HK1048999A1 (zh) 1999-09-28 2000-09-15 氮雜䓬吲衍生物，它們的製備和應用

Country Status (17)

Country Link
EP (1) EP1183259A2 (de)
JP (1) JP2003510328A (de)
KR (1) KR20010087401A (de)
CN (1) CN1374961A (de)
AU (1) AU1271201A (de)
BG (1) BG105650A (de)
BR (1) BR0007174A (de)
CA (1) CA2352194A1 (de)
CZ (1) CZ20012373A3 (de)
HK (1) HK1048999A1 (de)
HU (1) HUP0104917A3 (de)
IL (1) IL143349A0 (de)
NO (1) NO20012567L (de)
PL (1) PL347885A1 (de)
SK (1) SK8842001A3 (de)
TR (1) TR200101499T1 (de)
WO (1) WO2001023390A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6887996B2 (en) * 2000-12-01 2005-05-03 Guilford Pharmaceuticals Inc. Compounds and their use
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7786344B2 (en) 2002-07-26 2010-08-31 Basf Plant Science Gmbh Selection method
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
DK2305221T3 (en) 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000481A (es) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
AU2006222012B2 (en) 2005-03-08 2011-03-31 Basf Plant Science Gmbh Expression enhancing intron sequences
WO2006101937A1 (en) 2005-03-18 2006-09-28 Janssen Pharmaceutica N.V. Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
EP2188278A1 (de) 2007-09-14 2010-05-26 AstraZeneca AB Phthalazinonderivate
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
ME02640B (de) 2008-10-07 2017-06-20 Kudos Pharm Ltd Pharmazeutische formulierung 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2011064750A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
BR112012012588B1 (pt) 2009-11-27 2019-03-26 Basf Plant Science Company Gmbh Endonuclease, método para recombinação homóloga de polinucleotídeos e método para mutação direcionada de polinucleotídeos
AU2010325564A1 (en) 2009-11-27 2012-07-12 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
JP5813101B2 (ja) 2010-06-04 2015-11-17 アルバニー モレキュラー リサーチ， インコーポレイテッド グリシントランスポーター−１阻害剤、その作製方法および使用方法
PL3325623T6 (pl) 2015-07-23 2022-05-30 Institut Curie Zastosowanie skojarzenia cząsteczki dbait i inhibitorów parp do leczenia nowotworu
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
US20200129476A1 (en) 2017-04-28 2020-04-30 Akribes Biomedical Gmbh PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing
WO2018218025A1 (en) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
SG11202108399PA (en) * 2019-02-02 2021-09-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Indolo heptamyl oxime analogue as parp inhibitor
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202214649A (zh) * 2020-07-31 2022-04-16 大陸商正大天晴藥業集團股份有限公司 用作ｐａｒｐ抑制劑的吲哚并七員醯肟類似物的結晶及其製備方法
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011644A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
HRP20010573B1 (en) * 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas

Also Published As

Publication number Publication date
CZ20012373A3 (cs) 2002-05-15
BR0007174A (pt) 2001-09-04
CA2352194A1 (en) 2001-04-05
IL143349A0 (en) 2002-04-21
BG105650A (en) 2002-02-28
NO20012567L (no) 2001-06-25
TR200101499T1 (tr) 2002-09-23
WO2001023390A3 (de) 2001-12-27
HUP0104917A2 (hu) 2002-04-29
WO2001023390A2 (de) 2001-04-05
KR20010087401A (ko) 2001-09-15
SK8842001A3 (en) 2002-01-07
NO20012567D0 (no) 2001-05-25
HUP0104917A3 (en) 2002-12-28
AU1271201A (en) 2001-04-30
EP1183259A2 (de) 2002-03-06
JP2003510328A (ja) 2003-03-18
PL347885A1 (en) 2002-04-22
CN1374961A (zh) 2002-10-16

Similar Documents

Publication Publication Date Title
HK1048999A1 (zh) 氮雜䓬吲衍生物，它們的製備和應用
US7087637B2 (en) Substituted indoles which are PARP inhibitors
US6448271B1 (en) Substituted benzimidazoles and their use as parp inhibitors
EP1222191B1 (de) Benzodiazepin-derivate, deren herstellung und anwendung
WO2001057038A9 (de) Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
HK1041694A1 (zh) 2-苯基苯并咪唑化合物和2-苯基吲化合物，它们的制备和用途
WO2006006490A1 (ja) スピロ化合物
WO2021060453A1 (ja) 架橋型光学活性２級アミン誘導体
US20050153978A1 (en) Medicaments
US7026311B2 (en) Dibenzodiazepine derivatives, their preparation and use
US11091473B2 (en) Compounds for pain treatment, compositions comprising same, and methods of using same
MXPA01005199A (en) Azepinoindole derivatives, the production and use thereof
DE10039610A1 (de) Azepinoindol-Derivate, deren Herstellung und Anwendung
MXPA01005197A (en) Substituted benzimidazoles and their use as parp inhibitors